AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16483177
Drug: 0.250 mg
RxNorm normalized name: DIGOXIN 0.250 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.250 mg ganirelix sc daily for 7 days
Trial: 16483177
Drug: 0.500 mg
RxNorm normalized name: DOFETILIDE 0.500 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.500 mg ganirelix sc daily for 7 days
Trial: 10601934
Drug: Daily nonstress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily nonstress test
Trial: 10601934
Drug: Daily biophysical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily biophysical profile
Trial: 8848515
Drug: Mecamylamine (nicotinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecamylamine (nicotinic antagonist)
Trial: 2286929
Drug: Selective elimination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective elimination of oral flora
Trial: 31284490
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day anthocyanins (Group A)
Trial: 31284490
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg lutein and 2 mg zeaxanthin per day (Group X)
Trial: 31284490
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anthocyanins and xanthophylls (Group A+X)
Trial: 24389883
Drug: Lateral decubitus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral decubitus, knee-chest position (group L, n = 100)
Trial: 12052850
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (TDN)
Trial: 12052850
Drug: Nasal nicotine
RxNorm normalized name: nicotine Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal nicotine spray (NNS)
Trial: 10385777
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg aspirin daily (group A1)
Trial: 10385777
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg aspirin on alternate days (group A2)
Trial: 2370089
Drug: Product of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product of protein/creatinine ratio and estimated daily urinary creatinine excretion
Trial: 93179
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment (control)
Trial: 23999452
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin glargine titrated to a fasting glucose of ≤ 5.3 mmol/L (95 mg/dL)
Trial: 16781788
Drug: Omacor (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omacor (1 g/day)
Trial: 15347469
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus HRT
Trial: 9754466
Drug: Dialysis solution
RxNorm normalized name: dialysis solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysis solution containing 2.5% glucose
Trial: 9754466
Drug: Dialysis solution
RxNorm normalized name: dialysis solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysis solution containing 1.5% glucose
Trial: 8311013
Drug: Chemotherapy (CT:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT: cisplatin 50 mg/m2 + cyclophosphamide 600 mg/m2 day 1 every 28 days for 6 courses)
Trial: 30336702
Drug: Preferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preferred treatment (either Prolonged exposure or Sertraline)
Trial: 26701606
Drug: α-mangostin nanoparticles
RxNorm normalized name: mangostin
DrugBank: Mangostin (DB14371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-mangostin nanoparticles applied twice daily for 4 weeks
Trial: 23294853
Drug: 2-weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-weekly docetaxel (50 mg/m² on days 1 and 15 of a 4-week cycle)
Trial: 23294853
Drug: 3-weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-weekly docetaxel (75 mg/m² on day 1 of a 3-week cycle)
Trial: 18451243
Drug: 3-weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-weekly docetaxel
Trial: 21511218
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg clopidogrel loading dose (LD)
Trial: 21511218
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg clopidogrel loading dose (LD)
Trial: 21511218
Drug: Both 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 300 mg and 900 mg clopidogrel loading doses
Trial: 16595223
Drug: Drospirenone 3
RxNorm normalized name: drospirenone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone 3 mg and ethinyl estradiol 30 microg for 12 cycles
Trial: 10834865
Drug: Potent SAARD
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potent SAARD with a long lag time (intramuscular gold, if necessary replaced by D-penicillamine)
Trial: 9113250
Drug: 100-proof vodka
RxNorm normalized name: Clear Proof Acne Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-proof vodka (1.5 ml/kg) in orange juice
Trial: 8458059
Drug: 37.5 mg/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 mg/hr cimetidine
Trial: 8458059
Drug: 50 mg/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/hr cimetidine
Trial: 16049637
Drug: Rivastigmine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (mean dose 8.6 +/- 1.3 mg) for 12 months
Trial: 16049637
Drug: Rivastigmine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (mean dose 10.5-12 mg) for 12 months
Trial: 1457622
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg denbufylline BID
Trial: 6326784
Drug: Intravenous prenalterol
RxNorm normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous prenalterol (5 mg)
Trial: 6326784
Drug: Sustained oral
RxNorm normalized name: Sustain Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained oral prenalterol (100 mg twice a day)
Trial: 6326784
Drug: Placebo (during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (during oral crossover study)
Trial: 30983953
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (HAL-BWSTT and CPT)
Trial: 26266401
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (IPL + NIR + fractional Er:YAG laser)
Trial: 26266401
Drug: IPL monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPL monotherapy
Trial: 17468667
Drug: Structured Treatment
RxNorm normalized name: Lipid,structured (From Sunflower Oil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured Treatment Interruption (STI) arm
Trial: 15978307
Drug: Flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil 75 mg
Trial: 15978307
Drug: Flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil 50 mg vs 25 mg
Trial: 15978307
Drug: Flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil 75 mg vs 25 mg
Trial: 6277020
Drug: Guar-containing biscuit;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar-containing biscuit; specific dosage and duration not mentioned.
Trial: 31132118
Drug: Kisspeptin administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kisspeptin administration
Trial: 20701514
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 100 mg with FSH
Trial: 20701514
Drug: Letrozole 5
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole 5 mg daily with FSH
Trial: 20843911
Drug: Duloxetine 60‐120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60‐120 mg/day
Trial: 17414743
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR 75‐225 mg/day
Trial: 16288616
Drug: Capsaicin ointment
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin ointment
Trial: 10188750
Drug: Bench press-load
RxNorm normalized name: beach strawberry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bench press-load (BP-L)
Trial: 7797058
Drug: New anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New anti-inflammatory agents (methotrexate, hydroxychloroquine, auronifin, sulfonylureas)
Trial: 30782354
Drug: Self-reported medication
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported medication nonadherence measure
Trial: 16030053
Drug: Cinacalcet (initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (initiated at 30 mg, escalated to a maximum of 180 mg once daily)
Trial: 16030053
Drug: Cinacalcet (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (30 mg to 180 mg once daily)
Trial: 11799484
Drug: TAC, prednisone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC, prednisone, and MMF therapy (group T)
Trial: 11799484
Drug: TAC and
RxNorm normalized name: Nystatin and Triamcinolone Acetonide Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC and prednisone therapy (group D)
Trial: 6181324
Drug: BHT-933 5
RxNorm normalized name: BHT
DrugBank: Butylated hydroxytoluene (DB16863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BHT-933 5 mg
Trial: 31755968
Drug: Intravitreal ziv-aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ziv-aflibercept 1.25 mg
Trial: 31755968
Drug: Intravitreal ziv-aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ziv-aflibercept 2.5 mg
Trial: 27544361
Drug: Rectal indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal indomethacin (100mg)
Trial: 27544361
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline perfusion
Trial: 27544361
Drug: Rectal indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal indomethacin (100mg) and IV saline
Trial: 27544361
Drug: Rectal glycerin
RxNorm normalized name: glycerin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal glycerin (control)
Trial: 19223675
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (3x500 mg tablets per day for 12 days)
Trial: 15649728
Drug: 5000 IU
RxNorm normalized name: D 5000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 IU dalteparin injections once daily for 3 months
Trial: 15649728
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections once daily for 3 months
Trial: 10436143
Drug: Argatroban infusion
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Argatroban infusion therapy (continuous intravenous infusion for 60 minutes, repeated daily for 2 weeks)
Trial: 10436143
Drug: Argatroban infusion
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Argatroban infusion therapy
Trial: 7776528
Drug: Ketamine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.1 mg.kg‐1 + bupivacaine 5 ml
Trial: 7776528
Drug: Ketamine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.3 mg.kg‐1 + bupivacaine 5 ml
Trial: 7776528
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg.kg‐1 + bupivacaine 5 ml
Trial: 7776528
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine 5 ml only
Trial: 14688490
Drug: Multiple-drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-drug therapy
Trial: 31489467
Drug: Dried beancurd
RxNorm normalized name: peptone,dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried beancurd (100 g/day)
Trial: 31489467
Drug: Rice cake
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice cake (control group, 100 g/day)
Trial: 30417894
Drug: One injection
RxNorm normalized name: naloxone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection of pressed ceramic
Trial: 30417894
Drug: Two injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two injections of pressed ceramic
Trial: 30417894
Drug: Three injections
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three injections of pressed ceramic
Trial: 30417894
Drug: One injection
RxNorm normalized name: naloxone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection of pressed ceramic (aged)
Trial: 30417894
Drug: Two injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two injections of pressed ceramic (aged)
Trial: 30417894
Drug: Three injections
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three injections of pressed ceramic (aged)
Trial: 26770983
Drug: Acarbose (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (150 mg/day)
Trial: 22314263
Drug: Dextromethorphan/quinidine (DMQ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan/quinidine (DMQ) 45/30 mg
Trial: 22314263
Drug: Dextromethorphan/quinidine (DMQ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan/quinidine (DMQ) 30/30 mg
Trial: 7742436
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of Oka/Merck varicella vaccine
Trial: 7742436
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of Oka/Merck varicella vaccine
Trial: 2139442
Drug: Aspirin (324
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (324 mg/day)
Trial: 29514801
Drug: Intramuscular glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular glucocorticoid injection (40 mg triamcinolone acetate)
Trial: 26509817
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg IV methylprednisolone (neonate trial)
Trial: 26509817
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg IV methylprednisolone after anesthesia induction (ventricular septal defect trial)
Trial: 26509817
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg methylprednisolone in the cardiopulmonary bypass prime solution (ventricular septal defect trial)
Trial: 26509817
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg IV methylprednisolone (ventricular septal defect trial)
Trial: 24447620
Drug: Olesoxime (330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olesoxime (330 mg daily)
Trial: 19965659
Drug: MEL200 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEL200 (200 mg/m²)
Trial: 19965659
Drug: MEL100 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEL100 (100 mg/m²)
Trial: 18206857
Drug: 18 mg/day
RxNorm normalized name: lenvatinib mesylate 18 mg/day (10 mg x 1 and 4 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg/day prolonged-release methylphenidate
Trial: 18206857
Drug: 36 mg/day
RxNorm normalized name: scopolamine 0.3336 MG/Day 72 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 mg/day prolonged-release methylphenidate
Trial: 18206857
Drug: 72 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 72 mg/day prolonged-release methylphenidate
Trial: 16816797
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (olanzapine, quetiapine, risperidone, ziprasidone)
Trial: 16816797
Drug: Conventional antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antipsychotic (perphenazine)
Trial: 10845350
Drug: Preparation group
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation group (videotape shown the evening before surgery)
Trial: 8805113
Drug: 10% peppermint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% peppermint oil in ethanol solution
Trial: 8805113
Drug: Placebo (90%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (90% ethanol solution with traces of peppermint oil)
Trial: 1610539
Drug: Cholestyramine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (24 g daily)
Trial: 1610539
Drug: Lovastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (80 mg daily)
Trial: 6428899
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of hydroxy‐ethyl‐starch cryopreserved blood with free haemoglobin
Trial: 20447535
Drug: Low-level increases
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level increases in cTnI (0.04 microg/l to <0.1 microg/l)
Trial: 16225575
Drug: hCG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG treatment
Trial: 12405574
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (group A)
Trial: 12405574
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy only (group B)
Trial: 31977882
Drug: Supervised early
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised early exercise program in combination with standard treatment
Trial: 26179181
Drug: Citicoline (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (250 or 500 mg)
Trial: 25376719
Drug: Active hexose
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active hexose correlated compound (1.0 g/d for 4 weeks)
Trial: 23778476
Drug: 0.3% gatifloxacin/1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% gatifloxacin/1% prednisolone acetate fixed combination eye drops
Trial: 16717081
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Hb decrease of >3 g/dL
Trial: 16717081
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Hb decrease of 2.0-3.0 g/dL
Trial: 15259286
Drug: Oral continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral continuous combined E2 1 mg and NETA 0.25 mg
Trial: 15259286
Drug: Oral continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral continuous combined E2 1 mg and NETA 0.5 mg
Trial: 3901389
Drug: Org OD14
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org OD14 (2.5 mg daily for 12 weeks)
Trial: 31675674
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training combined with nutritional supplement (RTS)
Trial: 22036605
Drug: Intranasal hypocretin-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal hypocretin-1 (orexin A) (435 nmol)
Trial: 19644228
Drug: Fast-titration group
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-titration group (4 mg/24 h starting dose, increasing by 4 mg/24 h per week to a maximum of 24 mg/24 h)
Trial: 19644228
Drug: Slow-titration group
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-titration group (4 mg/24 h starting dose, increasing by 2 mg/24 h per week to a maximum of 24 mg/24 h)
Trial: 2660250
Drug: Propranolol, 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 160 mg daily for 6 months (n = 15)
Trial: 31897524
Drug: semaglutide 1.0
RxNorm normalized name: SEMAGLUTIDE 1.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [WEGOVY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide 1.0 mg once weekly
Trial: 31897524
Drug: canagliflozin 300
RxNorm normalized name: canagliflozin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: canagliflozin 300 mg once daily
Trial: 22132950
Drug: Febuxostat (approved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (approved doses)